Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

or

Watchlist | Portfolio

quotes
- Price Overview
- Performance Report
charts
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc (ACXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV Newsfile - Thu Mar 21, 6:16AM CDT

Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel...

Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection PR Newswire - Mon Oct 2, 2023

Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as...

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress PR Newswire - Tue Sep 12, 2023

Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted...

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 PR Newswire - Tue Aug 22, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update PR Newswire - Mon Jul 24, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023 PR Newswire - Tue Jun 20, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET PR Newswire - Thu Jun 15, 2023

/PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat...

Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire - Tue May 16, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Use your up/down arrows to move through the symbols.

Free Barchart Webinar